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ABSTRACT 
 
Niosomes formulation for the fixed dose combinations of amoxicillin-clavulanic acid  were prepared using Span 60 
and cholesterol by the ether injection method. Span 60 and cholesterol were added in various molar ratios to affect 
the vesicle membrane rigidity. Drugs combinations of amoxicillin-clavulanic acid entrapped in the bilayer of 
niosomes were quantified and the entrapment efficiency was found to be reaching up to 76%. The size and size 
distribution of niosomes were determined on light microscopy and transmission electron microscopy. The 
accelerated stability testing was used to predict the stability of the formulations. The test revealed changes in the 
characteristics of the liposomes. The in-vitro antibacterial assay of amoxicillin-clavulanic acid, revealed that 
niosomes formulations have stronger inhibitory activity. 
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Introduction 
 
Development of newer drugs is very difficult, 
expensive and rather time consuming due to its tedious 
preclinical and clinical testing. Improving safety and 
efficacy of existing drugs has been attempted using 
different methods such as therapeutic drug monitoring 
and targeted drug delivery etc [1]. Drug delivery 
systems could provide an extended drug bioavailability 
so that less drug is required for therapeutic 
effectiveness and reduces its toxicity [2].  
Recently, lipid and nonionic surfactant based drug 
delivery systems specifically niosomes have drawn 
much attention from researchers as potential carriers of 
various bioactive molecules that could be used for 
therapeutic applications. Several commercial niosome-
based drugs have already been marketed with a great 
success such as estradiol and dithranol [3, 4]. 
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Niosomes are vesicles composed mainly of hydrated 
non-ionic surfactants in addition to, in many cases, 
cholesterol or its derivatives. The unique structures of 
niosomes make it capable of encapsulating both 
hydrophilic and lipophilic substances. This can be 
achieved by entrapping hydrophilic in vesicular 
aqueous core or adsorbed on the bilayer surfaces while 
the lipophilic substances are encapsulated by their 
partitioning into the lipophilic domain of the bilayers 
[5]. Fixed-dose combination drugs (FDCs) are products 
that contain two or more active drugs in a fixed-dose 
ratio, and are useful for minimising pill burden and 
lowering cost. However, FDCs should ideally contain 
constituents that act via different mechanisms and do 
not cause additive toxic effects. At present, 118 
antibiotic FDCs are available on the Indian market 
[6].Antibiotic resistance is of increasing concern 
worldwide. Studies of several antibiotic combinations, 
such as amoxicillin-clavulanic acid, have reported 
additional advantage over their individual constituents, 
and have been reported to cause less toxic reactions 
and reduced resistance [7].Keeping these things in 
mind, the present is study focused on the design and 
development of dual drug loaded niosomes containing 
amoxicillin-clavulanic acid (Fig. 1). 
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Fig 1: Design of dual drug loaded niosomes 
 
Materials and Methods 
 
Preparation of niosomes 
Ether injection method: A mixture of Span 60 and 
cholesterol in different ratio was added to a beaker 
containing 10 ml diethyl ether organic solvent. To this 
mixture, 250 mg of amoxycillin was added portion 
wise with continuous stirring and maintaining a 
temperature of 30 ºC. This heated solution was finally 
filled in a 20 mL syringe. A solution 125 mg clavulanic 
acid dissolved in 10 mL phosphate-buffered saline was 
prepared separately. The contents of the syringe were 
injected drop wise into a mixture with continuous 
stirring [8]. 
Determination of niosome size 
Niosomes, similar to liposomes, assume spherical 
shape and so their diameter can be determined using 
light microscopy, photon correlation microscopy and 
freeze fracture electron microscopy. Freeze thawing 
(keeping vesicles suspension at – 20°C for 24 hrs and 
then heating to ambient temperature) of Niosomes 
increases the vesicle diameter, which might be 
attributed to fusion of vesicles during the cycle. 
Morphology analysis of niosomes 
Morphology analysis of niosomes was carried out by 
negative staining transmission electron microscopy 
(NS-TEM), using a JEOL-2000 Ex II TEM (Japan). A 
drop of the niosomal formulation was placed on a 
carbon coated copper grid, and the sample excess was 
removed with filter paper. Then a drop of 2% (w/v) 
PTA (phosphotungsic acid solution) was applied to the 
carbon gridand left to stand for 2 min. Once the excess 
staining agent was removed with filter paper, the 
sample was air-dried and the thin film of stained 
niosomes was observed with the transmission electron 
microscope. 
 
Drug entrapment efficiency of niosomes  
After preparing niosomal dispersion, unentrapped drug 
is separated by dialysis, centrifugation, or gel filtration 
and the drug remained entrapped in niosomes is 
determined by complete vesicle disruption using 50% 
n-propanol or 0.1% Triton X-100 and analysing the 
resultant solution by appropriate assay method for the 
drug. Where, 
Entrapment efficiency (EF) = (Amount entrapped / 
total amount) x 100 
In-vitro release 
A method of in-vitro release rate study includes the use 
of dialysis tubing. A dialysis sac is washed and soaked 
in distilled water. The vesicle suspension is pipetted 
into a bag made up of the tubing and sealed. The bag 
containing the vesicles is placed in 200 ml of buffer 
solution in a 250 ml beaker with constant shaking at 
25°C or 37°C. At various time intervals, the buffer is 
analyzed for the drug content by an appropriate assay 
method. 
Antibacterial Assay 
For the in vitro antibacterial assay of formulations 
were studied on bacteria S. aureus. The cultures were 
grown on nutrient agar at 37 °C for 18 h and the 
colonies were suspended in saline (0.85% NaCl) and its 
turbidity was adjusted to 0.5 Mac Farland standards 
(108 CFU/mL). This saline culture preparation was 
used to inoculate the plates. In the agar disc diffusion 
method the standard drugs and formulations were 
introduced into a disc 0.5 mm (hi-media) and then 
allowed to dry. Thus the disc was completely saturated 
with the test compound at concentration of 10 mg/mL. 
Then these discs were placed directly on the surface of 
Muller Hinton agar plates, swabbed with the test 
organism and the plates were incubated at 37 °C for 24 
h [9]. 
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Results and Discussion 
 
Preparation of niosomes 
Niosomal formulations of amoxycillin- clavulanic acid 
were prepared with Span 60 
as surfactants (Table 1).  
Span 60 yields very stable niosomes with a narrow 
particle size distribution but they exhibit rather low 
entrapment efficiency. By adding cholesterol to 
surfactant in a 1:1 weight ratio both stability and 
entrapment efficiency increased. In addition, surface of 
Span 60 niosomes is flexible due to their head group 
structure. The AC1niosomes have greater entrapment 
efficiency and least mean particle size (Fig. 2 and 3). 
The efficiency increases when low mechanical 
agitation speeds are used in the first stage of the 
preparation Protocol.  
 
Table 1: Formulation of Niosomes 
 
S. No. Formulation Code Span 60 Cholesterol Solvent Drugs 
1. AC1 50 mg 50 mg 10 mL DEA 250 mg amoxycillin + 125 mg clavulanic acid 
2 AC2 50 mg 100 mg 10 mL DEA 250 mg amoxycillin + 125 mg clavulanic acid 
3 AC3 100 mg 50 mg 10 mL DEA 250 mg amoxycillin + 125 mg clavulanic acid 
 
 
 
Fig 2: Drug entrapment efficiency of niosomal formulations 
 
Fig 3: Mean particle size of niosomal formulations 
 
Transmission Electron Microscopy (TEM) 
Fig 4 shows the transmission electron 
microphotographs of formula F8, as a representative 
sample, that was composed of Span 60 with cholesterol 
in equimolar ratio. TEM employed here to picture 
directly the shape and size of TMC loaded niosomes. 
As occur in the images the niosomes appears as 
numerous scattered spherical dark stained micron 
vesicles with well-identified outline and core. 
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Fig 4: Representative TEM of AC1 niosome (A) (scale bar = 20 μm); (B) (scale bar = 8 μm) 
 
In-vitro release study 
Release data expressed as percent drug released over 8 
hours determined for three formulations are shown in 
Fig. 5. The release profile of the free unentrapped 
amoxicillin and pot clavulanate showed that 75% of the 
drug was released within one hour. In comparison, the 
release profile of amoxycillin from the niosomal 
formulations showed that 72.4% of the drug was 
released in 8 hours, reflecting the sustained release of 
amoxycillin from the niosomal formulations. Similarly, 
the release profile of pot. clavulanate from the 
niosomal formulations showed that 78.4% of the drug 
was released in 8 hours. The results of release profiles 
of the binary drugs indicate the effect on release of the 
changes in proportion of free to niosome-entrapped 
drug in the prepared formulations. 
 
Table 2: Release profiles of noisome formulations 
 
S.No. Formulation Amoxycillin(% Drug Release) Clavulanic(% Drug Release) 
   0 h 1 h 2 h 4 h 6 h 8 h 0h 1 h 2 h 4 h 6 h 8 h 
1 AC1 0 28.6 44.4 60.12 69.01 72.4 0 32.6 48.96 60.11 70.6 78.4 
2 AC2 0 26.18 42.44 58.3 64.6 70.22 0 28.66 37.3 50.12 64.2 70.02 
3 AC3 0 23.4 36.2 50.04 59.6 66.7 0 26.7 37.2 50.7 61.6 71.5 
 
 
Fig 5: % Drug released of drugs in noisome over 8 hours 
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Fig 6: Best fitted Higuchi model of amoxicillin and clavulanic acid release in AC1 
 
Compatibility studies: Excipients compatibility 
studies the results depicts there was no change in color, 
no lump formation occurred in any of the mixture at 
different temperature & humidity conditions, when 
observed on different days (7th, 15, 30th days) interval 
in comparison to initial observation on 0th day. This 
confirmed that both the drugs were compatible with 
each other as well as with excipients. Rf values 
obtained from TLC studies on (7th, 15, 30th days) were 
approximately similar to Rf values of pure drugs and 
niosomes obtained on 0th day, predicting the 
compatibility of both drugs with gel excipients. 
 
 
FT IR: Drug excipients interaction was also checked 
out by comparing the FTIR spectra of pure drug 
amoxycillin trihydrate, clavulanate potassium and 
FTIR spectra of the physical mixture of drugs with 
excipients; span 60 and cholesterol. The FTIR spectra 
in this region of amoxicillin-clavulanic acidbinary 
system, of molar ratio 1:1, are shown in Fig. 
Frequencies assigned to aromatic C=C, to νNH, to 
amidic νC=O, to β-lactamic C=O (νC=O), and to 
carboxylate (νsCOO−) (νasCOO−), have all been 
identified in free amoxicillin-clavulanic acid and are 
reported in Table. IR spectra indicate no significant 
difference in characteristic peak at wave numbers of 
the drug in presence of the excipient. Thus, IR spectra 
indicated no drug-excipient interaction. 
 
Table 3: Assignment of relevant IR absorption bands of amoxicillin-clavulanic acid and noisome 
formulation 
 
Assignment Amoxycillin(cm
-1
) Pot. clavulanate(cm
-1
) Formulation AC1 (cm
-1
) 
υc=o (β-lactamic) 1774 1751 1774, 1743 
υc=o (amide) 1685 - 1685 
C=C (Aromatic) 1585 - 1581 
υ(coo-) 1577 1519 1577, 1519 
υNH(β-lactamic) 1519 - 1519 
y = 26.57x + 2.8347 
R² = 0.9807 
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Fig 7: IR spectrum of formulation AC1 
 
HPLC: The evaluation of the stability and 
compatibility of amoxycillin and pot. clavulanate 
binary mixtures with the span 60 and cholesterol after 
one month at 40 °Cand 75% RH was conducted using 
the HPLC-UV method described in the relevant USP 
monograph. The response was linear within the range 
studied (R² = 0.9882). The HPLC-UV method for 
quantitation of amoxycillin and pot. clavulanate can 
detect thermal degradation and chemical interactions 
with excipients, which decrease the concentration of 
drugs. The chromatograms of binary mixtures are 
shown in Figure. No alteration in peak area was 
detected, indicating that these excipients have 
sufficient compatibility for use in noisome formulation 
of amoxycillin and pot. clavulanate. 
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Fig 8: HPLC chromatogram of standard of amoxycillin and pot. clavulanate binary mixtures 
  
Antibacterial assay: The antibacterial effects of the 
formulations AC1, AC2 and AC3 were studied against 
the S. aureusand compared with the standard drug 
augmentin at the same concentration level. The results 
clearly showed that the formulation AC1 inhibited S. 
aureus22.00 mm, whereas AC2 and AC3 inhibited 
10.00 mm and 11.00 mm, respectively (Fig. 9). The 
standard drug augmentin inhibited 18.00 mm. These 
results indicate the promising effects of formulation 
AC1 against the bacteria S. aureus. 
 
Fig 9: Zone of inhibition of niosomal formulations 
 
Conclusion 
 
Niosomes prepared from Span 60-cholesterol were able 
to encapsulate amoxycillin and clavulanic acid. 
Average size, stability and RSV entrapment efficiency 
of niosomes are linked not only to their composition 
but also to the protocol employed in preparing the 
niosomes. Optimized concentration of span 60 and 
cholesterol was found to be 1:1.In the in-vitro study, 
niosomes formulation of AC1 showed high percentage 
of drug release, 72.4 to 78.4% for about 8 hrs. This 
indicated that this batch of niosomes formulation 
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exhibit sustained drug release pattern as the niosomes 
act as reservoir system for continuous delivery of drug. 
Niosomes formed which were observed under 
transmission electron microphotographs were mostly 
spherical and in medium to slightly large size. In 
stability studies, the optimized formulation, AC1 
Stability started to deteriorate from 2
nd
 week where the 
niosomes vesicles are seen in non-spherical shape. On 
21st and 28th day the niosomes formulation were 
examined and seen in non-spherical shape and are 
clumped for both storage condition. This is mainly due 
to disruption or aggregation of vesicles since it is 
exposed to chemical degradation like hydrolysis and 
oxidation. As for the drug release, niosomes 
formulation stored in room temperature and 
refrigerated condition showed 88.29% which mainly 
due to membrane-stabilizing effect of cholesterol. 
Thus, from the prepared niosomes formulation, it can 
be concluded that the vesicular system was more stable 
at 2ºC-8ºC. The released data of optimized niosomes 
formulation AC1 of amoxicillin were analysed 
mathematically according to zero order, first order, and 
Higuchi equations. As for the Higuchi’s model 
(r
2
=0.980), First order (r
2
=0.938), and zero order 
(r
2
=0.833) regression co-efficient obtained. The 
amoxicillin drug release from niosomes does not obey 
first order kinetics, which means that the release of 
amoxicillin from the niosomes vesicle is independent 
to concentration gradient. Similarly, for clavulanic acid 
regression co-efficient obtained as Higuchi’s model 
(r
2
=0.983), First order (r
2
=0.962), and zero order 
(r
2=0.835). Best fitted Higuchi’s model indicates that 
the drug release by diffusion.  
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